0001437749-22-011649 | 10-Q | XBRL Viewer

Print Document View Excel Document

Document And Entity Information - shares	3 Months Ended
Document And Entity Information - shares	Mar. 31, 2022	May 10, 2022
Document Information [Line Items]
Entity Central Index Key	0001375195
Entity Registrant Name	CORETEC GROUP INC.
Amendment Flag	false
Current Fiscal Year End Date	--12-31
Document Fiscal Period Focus	Q1
Document Fiscal Year Focus	2022
Document Type	10-Q
Document Quarterly Report	true
Document Period End Date	Mar. 31, 2022
Document Transition Report	false
Entity File Number	000-54697
Entity Incorporation, State or Country Code	OK
Entity Tax Identification Number	73-1479206
Entity Address, Address Line One	600 S. Wagner Rd.
Entity Address, City or Town	Ann Arbor
Entity Address, State or Province	MI
Entity Address, Postal Zip Code	48103
City Area Code	866
Local Phone Number	916-0833
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		255,615,791

Condensed Consolidated Balance Sheets (Unaudited) - USD ($)	Mar. 31, 2022	Dec. 31, 2021
Current assets:
Cash	$ 3,560,954	$ 4,053,327
Prepaid expenses	105,739	133,491
Total current assets	3,666,693	4,186,818
Property and equipment, net	5,837	0
Other assets:
Intangibles, net	968,947	989,604
Goodwill	166,000	166,000
Deposits-other	69,196	16,343
Total other assets	1,204,143	1,171,947
Total Assets	4,876,673	5,358,765
Current liabilities:
Accounts payable and accrued expenses	401,342	307,096
Total current liabilities	401,342	307,096
Long term debt, net	1,202,251	1,187,518
Total Liabilities	1,603,593	1,494,614
Stockholders' equity:
Preferred stock, Series A convertible, $0.0002 par value, 500,000 shares authorized; 345,000 shares issued and outstanding at March 31, 2022 and December 31, 2021	69	69
Common stock $0.0002 par value, 1,500,000,000 shares authorized; 255,615,791 and 254,055,581 shares issued and outstanding at March 31, 2022 and December 31, 2021, respectively.	51,121	50,809
Additional paid-in capital	17,383,221	17,295,262
Accumulated deficit	(14,161,331)	(13,481,989)
Total Stockholders' Equity	3,273,080	3,864,151
Total Liabilities and Stockholders' Equity	$ 4,876,673	$ 5,358,765

Condensed Consolidated Balance Sheets (Unaudited) (Parentheticals) - $ / shares	Mar. 31, 2022	Dec. 31, 2021
Preferred stock, par value (in dollars per share)	$ 0.0002	$ 0.0002
Preferred stock, shares authorized (in shares)	500,000	500,000
Preferred stock, shares issued (in shares)	345,000	345,000
Preferred stock, shares outstanding (in shares)	345,000	345,000
Common stock, par value (in dollars per share)	$ 0.0002	$ 0.0002
Common stock, shares authorized (in shares)	1,500,000,000	1,500,000,000
Common stock, shares issued (in shares)	255,615,791	254,055,581
Common stock, shares outstanding (in shares)	255,615,791	254,055,581

Condensed Consolidated Statements of Operations (Unaudited) - USD ($)	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Income:
Revenue	$ 0	$ 0
Expenses:
Research and development	198,494	37,601
General and administrative	433,323	342,458
Interest	47,990	58,362
Total expenses	679,807	438,421
Other income	465	0
Net loss	$ (679,342)	$ (438,421)
Loss per share:
Basic and diluted (in dollars per share)	$ (0.003)	$ (0.002)
Weighted average shares outstanding, basic and diluted (in shares)	254,932,103	222,856,458

Condensed Consolidated Statements of Changes in Stockholders' Equity (Unaudited) - USD ($)	Cumulative Effect, Period of Adoption, Adjustment [Member] Preferred Stock [Member] Series A Preferred Stock [Member]	Cumulative Effect, Period of Adoption, Adjustment [Member] Common Stock [Member]	Cumulative Effect, Period of Adoption, Adjustment [Member] Additional Paid-in Capital [Member]	Cumulative Effect, Period of Adoption, Adjustment [Member] Retained Earnings [Member]	Cumulative Effect, Period of Adoption, Adjustment [Member]	Preferred Stock [Member] Series A Preferred Stock [Member]	Common Stock [Member]	Additional Paid-in Capital [Member]	Retained Earnings [Member]	Total
Balance (in shares) at Dec. 31, 2020	0	0				345,000	213,751,145
Balance at Dec. 31, 2020	$ 0	$ 0	$ (988,900)	$ 126,125	$ (862,775)	$ 69	$ 42,750	$ 8,033,313	$ (7,339,175)	$ 736,957
Options issued for compensation and services						$ 0	$ 0	18,723	0	18,723
Common stock issued for liabilities (in shares)						0	1,716,447
Common stock issued for liabilities						$ 0	$ 343	69,921	0	70,264
Exchange of stock options for common stock (in shares)						0	1,200,000
Exchange of stock options for common stock						$ 0	$ 240	(240)	0	0
Net loss for the period						$ 0	$ 0	0	(438,421)	(438,421)
Debt converted to common stock (in shares)						0	1,519,757
Debt converted to common stock						$ 0	$ 304	49,696	0	50,000
Private placement stock issuance (in shares)						0	23,500,000
Private placement stock issuance						$ 0	$ 4,700	4,908,500	0	4,913,200
Warrants issued						$ 0	$ 0	62,785	0	62,785
Balance (in shares) at Mar. 31, 2021						345,000	241,687,349
Balance at Mar. 31, 2021						$ 69	$ 48,337	12,153,798	(7,651,471)	4,550,733
Balance (in shares) at Dec. 31, 2021						345,000	254,055,581
Balance at Dec. 31, 2021						$ 69	$ 50,809	17,295,262	(13,481,989)	3,864,151
Options issued for compensation and services						$ 0	$ 0	70,973	0	70,973
Common stock issued for liabilities (in shares)						0	660,210
Common stock issued for liabilities						$ 0	$ 132	17,166	0	$ 17,298
Exchange of stock options for common stock (in shares)						0	900,000			900,000
Exchange of stock options for common stock						$ 0	$ 180	(180)	0	$ 0
Net loss for the period						$ 0	$ 0	0	(679,342)	(679,342)
Balance (in shares) at Mar. 31, 2022						345,000	255,615,791
Balance at Mar. 31, 2022						$ 69	$ 51,121	$ 17,383,221	$ (14,161,331)	$ 3,273,080

Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Cash Flows from Operating Activities
Net loss	$ (679,342)	$ (438,421)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation	99	0
Amortization - intangibles	20,657	20,057
Amortization - debt discount	14,733	21,526
Options issued for services	70,973	18,723
Change in:
Prepaid expenses	27,752	25,158
Deposits	(52,853)	(12,750)
Accounts payable and accrued liabilities	111,545	346,492
Net cash used in operating activities	(486,436)	(19,215)
Cash Flows from Investing Activities
Purchases of equipment	(5,936)	0
Cash Flows from Financing Activities
Payments on notes payable	0	(23,181)
Proceeds from debt and warrants issued	0	334,651
Proceeds from private placement stock issued	0	4,913,200
Net cash provided by financing activities	0	5,224,670
Net change in cash	(492,372)	5,205,455
Cash, beginning of period	4,053,327	22,219
Cash, end of period	3,560,954	5,227,674
Supplemental Disclosure of Cash flow Information
Cash paid during the period for interest	33,298	33,603
Non-Cash Financing Activities
Notes payable converted to common stock	0	50,000
Stock options exchanged for common stock	180	240
Common stock issued to satisfy liabilities	$ 17,298	$ 70,264

Note 1 - Business Organization, Nature of Business and Basis of Presentation

3 Months Ended

Mar. 31, 2022

Notes to Financial Statements

Business Description and Basis of Presentation [Text Block]

Note 1 – Business Organization, Nature of Business and Basis of Presentation

Nature of Business

The Coretec Group Inc. (the “Group”) (formerly 3DIcon Corporation) (“3DIcon”) was incorporated on August 11, 1995, under the laws of the State of Oklahoma as First Keating Corporation. The articles of incorporation were amended August 1, 2003 to change the name to 3DIcon Corporation. During 2001, First Keating Corporation began to focus on the development of 360-degree holographic technology. From January 1, 2001, 3DIcon’s primary activity has been the raising of capital in order to pursue its goal of becoming a significant participant in the development, commercialization and marketing of next generation 3D display technologies.

Coretec Industries, LLC (“Coretec”), a wholly owned subsidiary of the Group (collectively the “Company”), was organized on June 2, 2015 in the state of North Dakota. Coretec is currently developing, testing, and providing new and/or improved technologies, products, and service solutions for energy-related industries including, but not limited to oil/gas, renewable energy, and distributed energy industries. Many of these technologies and products also have application for medical, electronic, photonic, display, and lighting markets among others. Early adoption of these technologies and products is anticipated in markets for energy storage (Li-ion batteries), renewable energy (BIPV), and electronics (Asset Monitoring).

Basis of Presentation

The accompanying condensed consolidated financial statements of the Company have been prepared without audit pursuant to the rules and regulations of the Securities and Exchange Commission (“SEC”). Certain information and footnote disclosures normally included in the consolidated financial statements prepared in accordance with accounting principles generally accepted in the United States of America have been condensed or omitted pursuant to such rules and regulations. The Company believes that the disclosures made are adequate to make the information presented not misleading. These condensed consolidated financial statements should be read in conjunction with the Company’s year-end audited consolidated financial statements and related footnotes included in the previously filed Form 10-K, and in the opinion of management, reflects all adjustments necessary to present fairly the consolidated financial position of the Company. The consolidated results of operations for interim periods may not be indicative of the results which may be realized for the full year.

Note 2 - Summary of Significant Accounting Policies

3 Months Ended

Mar. 31, 2022

Notes to Financial Statements

Business Description and Accounting Policies [Text Block]

Note 2 – Summary of Significant Accounting Policies

Principles of Consolidation

The condensed consolidated financial statements include the accounts of the Group and its wholly owned subsidiary, Coretec. Intercompany transactions and balances have been eliminated in consolidation.

Use of Estimates

The preparation of condensed consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenues, expenses and the disclosure of contingent assets and liabilities. Actual results could differ from the estimates and assumptions used.

Property and Equipment

Property and equipment is recorded at cost. Depreciation is recorded over the estimated useful lives using the straight-line method. Maintenance and repairs are expensed as incurred; major improvements and betterments are capitalized.

Intangibles

Intangible assets consist of purchased patents and capitalized website costs. Intangible assets are recorded at the fair value as of the date of acquisition, and intangible assets with finite lives are amortized on a straight-line basis over their estimated useful lives.

Goodwill

The Company evaluates the carrying value of goodwill on an annual basis and between annual evaluations if events occur or circumstances change that would more likely than not reduce the fair value of goodwill below its carrying amount. When assessing whether goodwill is impaired, management considers first a qualitative approach to evaluate whether it is more likely than not the fair value of the goodwill is below its carrying amount; if so, management considers a quantitative approach by analyzing changes in performance and market-based metrics as compared to those used at the time of the initial acquisition. For the periods presented, no impairment charges were recognized.

Impairment of Long-Lived Assets

Long-lived assets, such as property and equipment and intangible assets, are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. If circumstances require a long-lived asset or asset group be tested for possible impairment, the Company first compares undiscounted cash flows expected to be generated by that asset or asset group to its carrying value. If the carrying value of the long-lived asset or asset group is not recoverable on an undiscounted cash flow basis, impairment is recognized to the extent that the carrying value exceeds its fair value. Fair value is determined through various valuation techniques including discounted cash flow models, quoted market values and third-party independent appraisals, as considered necessary.

Fair Value of Financial Instruments

The following methods and assumptions were used to estimate the fair value of each class of financial instrument held by the Company:

Current assets and current liabilities – The carrying value approximates fair value due to the short maturity of these items.

Notes payable – The fair value of the Company’s notes payable has been estimated by the Company based upon the liability’s characteristics, including interest rates, embedded instruments and conversion discounts. The carrying value approximates fair value.

Basic and Diluted Loss Per Common Share

Basic loss per common share is computed by dividing net loss by the weighted average number of vested common shares outstanding during the period. Diluted loss per share reflects the potential dilution that could occur if securities or other instruments to issue common stock were exercised or converted into common stock. The following securities are excluded from the calculation of weighted average dilutive common shares because their inclusion would have been anti-dilutive:

March 31,

2022

2021

Options
53,161,609 18,212,174

Warrants
142,604,000 142,604,000

Series A convertible preferred stock
115,000 115,000

Convertible debt
39,836,388 47,720,365

Total potentially dilutive shares
235,716,997 208,651,539

Research and Development

Research and development costs are expensed as incurred.

Subsequent Events

The Company evaluates events that have occurred after the balance sheet date but before the condensed consolidated financial statements are issued. Based upon the evaluation, the Company did not identify any recognized or non-recognized subsequent events that would have required adjustment or disclosure in the consolidated financial statements.

Income Taxes

The Company accounts for income taxes under an asset and liability approach that requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been recognized in the Company’s consolidated financial statements or tax returns. In estimating future tax consequences, the Company generally considers all expected future events other than enactments of changes in tax laws or rates. The effect on deferred tax assets and liabilities of a change in tax rates will be recognized as income or expense in the period that includes the enactment date. A valuation allowance is established when necessary to reduce deferred tax assets to the amount expected to be realized.

The Company’s tax benefits are fully offset by a valuation allowance due to the uncertainty that the deferred tax assets would be realized. Management considers the likelihood of changes by taxing authorities in its filed income tax returns and recognizes a liability for or discloses potential changes that management believes are more likely than not to occur upon examination by tax authorities. Management has not identified any uncertain tax positions in filed income tax returns that require recognition or disclosure in the accompanying consolidated financial statements.

Recent Accounting Pronouncements

The following is a summary of recent accounting pronouncement recently adopted by the Company:

In May 2021, the FASB issued ASU 2021-04, Issuer’s Accounting for Certain Modifications or Exchanges of Freestanding Equity-Classified Written Call Options which clarifies the accounting for a modification or an exchange of a freestanding equity-classified written call option that remains equity classified after a modification or exchange and the related EPS effects of such transaction if recognized as an adjustment to equity. The Company adopted ASU 2021-04 on January 1, 2022. The Company will consider this guidance for modifications or exchanges of freestanding equity-classified written call options.

Note 3 - Intangibles

3 Months Ended

Mar. 31, 2022

Notes to Financial Statements

Intangible Assets Disclosure [Text Block]

Note 3 – Intangibles

The following table sets forth patents:

	March 31,			December 31,
Patents	*2022*			*2021*
Gross Carrying Amount	$	1,400,000		$	1,400,000
Accumulated Amortization		(441,260	)		(421,203	)
	$	958,740		$	978,797

The patents were obtained with the September 30, 2016 reverse acquisition of the 3DIcon Corporation. Amortization expense for the next five fiscal years and thereafter is expected to be approximately $80,000 annually through the year ended December 31, 2034.

Intangible assets include $12,007 of capitalized website costs during 2021. Accumulated amortization was $1,800 and $1,200 as of March 31, 2022 and December 31, 2021, respectively. Amortization expense for the next five fiscal years is expected to be approximately $2,400, annually.

Note 4 - Notes Payable

3 Months Ended

Mar. 31, 2022

Notes to Financial Statements

Debt Disclosure [Text Block]

Note 4 –Notes Payable

	March 31,			December 31,
Long term debt:	2022			2021
10% Promissory note due January 2024	$	1,310,617		$	1,310,617
Less:
Warrants issued		(82,672	)		(93,929	)
Debt issue costs		(25,694	)		(29,171	)
Total long term debt	$	1,202,251		$	1,187,518

10% Promissory note due January 2024, net

On October 4, 2019, the Company entered into a Credit Agreement and related Promissory Note with Diversified Alpha Fund of Navigator Global Fund Manager Platform SPC (“DAF”), the Lender. DAF is a segregated portfolio fund of Navigator Global Fund Manager Platform SPC. DAF is managed and controlled by Mollitium Investment Management (Mollitium). Mollitium utilizes Diversified Global Investment Advisors Ltd. (“DGIA”) to act in an advisory role. DGIA maintains an Investment Committee to support the services to Mollitium. Simon Calton serves as part of this five-member investment committee and in accordance with the investment committee’s guidelines, Mr. Calton does not participate in matters or voting that pertain to the Company due to his conflict of interest. Investment advice provided by DGIA to Mollitium are recommendations only and the final decision on actions are the responsibility of Mollitium. Carlton James Global Management, Ltd (CJGM) serves as a distributer of investments by introducing funds available to the market of which DAF is included in CJGM’s group of funds. Compensation to CJGM occurs when investments are made into funds that they introduce. CJGM is part of the Carlton James Group of which Mr. Calton is CEO.

The 10% Promissory Note, in a principal amount of $2,500,000, is due on the 15th day of the 4th anniversary of each advance with the first capital payment due on March 15, 2024. The Promissory Note has attached warrants to subscribe for and purchase 3,000,000 shares of common stock at an exercise price of $0.052 per share. Under the terms of the Credit Agreement, DAF will fund the Promissory Note in sixteen (16) tranches in amounts of $125,000 and $175,000 per month beginning in October 2019. The funding of the Promissory Note is at the discretion of DAF and may differ from the planned schedule. As of December 31, 2021, DAF has advanced $2,170,000 with no definitive date or commitment to advance the remaining $330,000. Interest is accrued monthly and paid in advance for the first 12 months and thereafter interest only payments shall be paid quarterly.

On November 16, 2021, the Company countersigned a letter of variation (the Variation) to the credit agreement entered into, on October 4, 2019, with DAF. Pursuant to the Variation, the Lender agreed to extend the repayment days for each advance made by Lender under the credit agreement until the fourth anniversary of such advance. DAF has also communicated to the Company that interest only payments are due on a quarterly basis, commencing in January of 2022.

Under the terms of the Promissory Note, DAF has the right to elect to convert all or part of the Promissory Notes at a price equal to seventy percent (70%) of the average closing price of the Company’s common stock as reported on the over-the-counter quotation system on the OTC Markets during the fifteen (15) calendar days prior to the loan closing date of October 4, 2019, which calculates to $0.0329 per share.

Under the terms of the Credit Agreement, warrants to subscribe for and purchase 3,000,000 shares of common stock at an exercise price of $0.052 per share were issued to DAF. The estimated value of the warrants granted monthly, with each advance, is calculated using the Black-Scholes option pricing model. The resulting estimated value of the warrant is used to proportionally allocate the fair value of the debt advance and the fair value of the warrants.

There were no warrants issued under the Credit Agreement during the three months ended March 31, 2022. The allocated cost of the warrants issued amounted to $62,784 during the three months ended March 31, 2021, and is being amortized over the life of the debt. $11,257 and $11,088 was amortized during the three months ended March 31, 2022 and 2021, respectively.

Additionally, under the terms of the Credit Agreement, the Company agreed to pay a commitment fee of 3% of each advance and reimburse DAF for certain expenses in connection with the preparation, interpretation, performance and enforcement of the Credit Agreement. Those costs are being amortized over the life of the debt. The Company amortized $3,476 and $3,656 during the three months ended March 31, 2022 and 2021, respectively.

- Definition

The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-URI https://asc.fasb.org/topic&trid=2208564

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 20
-Section 50
-Paragraph 1B
-Subparagraph (h)
-URI https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 20
-Section 50
-Paragraph 1C
-Subparagraph (c)
-URI https://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 20
-Section 50
-Paragraph 1I
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 20
-Section 50
-Paragraph 1I
-Subparagraph (d)
-URI https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(c))
-URI https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 20
-Section 50
-Paragraph 1B
-Subparagraph (g)
-URI https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 20
-Section 50
-Paragraph 1C
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 20
-Section 50
-Paragraph 1C
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 20
-Section 50
-Paragraph 1E
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 20
-Section 50
-Paragraph 1B
-URI https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 20
-Section 50
-Paragraph 1I
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 20
-Section 50
-Paragraph 1B
-Subparagraph (i)
-URI https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611

+ Details

Note 5 - Commitments and Contingencies

3 Months Ended

Mar. 31, 2022

Notes to Financial Statements

Commitments and Contingencies Disclosure [Text Block]

Note 5 – Commitments and Contingencies

Warrants

Warrants to subscribe for and purchase up to 3,000,000 shares of common stock at an exercise price of $0.052 per share were included under the terms of the DAF Credit Agreement. The warrants will be issued in amounts of 150,000 and 210,000 per month during the funding period. In the event that funding advances deviate from the planned schedule then warrants will be issued pro-rata at 1.2 warrants for every $1 of funding. Warrants granted under the terms of the DAF Credit Agreement as of March 31, 2022 total 2,604,000. The estimated value of the warrants granted monthly, with each advance, is calculated using the Black-Scholes option pricing model. The expected dividend yield is based on the average annual dividend yield as of the grant date. Expected volatility is based on the historical volatility of our stock. The risk-free interest rate is based on the U.S. Treasury Constant Maturity rates as of the grant date. The expected life of the warrant is based on historical exercise behavior and expected future experience. The resulting estimated value of the warrant is used to proportionally allocate the fair value of the debt advance and the fair value of the warrants.

On March 2, 2021, the Company entered into a securities purchase agreement (the “Purchase Agreement”) with a single institutional investor in a private placement to sell (i) 23,500,000 shares of its common stock, (ii) pre-funded warrants to purchase up to an aggregate of 51,500,000 shares of its common stock, and (iii) warrants to purchase up to an aggregate of 82,500,000 shares of its common stock for gross proceeds of approximately $6,000,000. The combined purchase price for one share of common stock and associated Warrant is $0.08 and for one Pre-Funded Warrant and associated Warrant is $0.0799. The sale of the securities under the Purchase Agreement closed on March 5, 2021. The pre-funded warrants have an exercise price of $0.0001 per share, subject to adjustment as set forth in the pre-funded warrants for stock splits, stock dividends, recapitalizations and similar events. The pre-funded warrants will be exercisable immediately and may be exercised at any time until all of the pre-funded warrants are exercised in full. In addition, the Company agreed to issue to the placement agent (or its designees) warrants to purchase a number of shares equal to 8.0% of the aggregate number of shares and pre-funded warrant shares sold under the Purchase Agreement, or warrants to purchase an aggregate of up to 6,000,000 shares. The placement agent warrants generally will have the same terms as the warrants, except they will have an exercise price of $0.10.

Warrants Summary

There was no warrant activity for the three months ended March 31, 2022. The following table summarizes the Company’s warrants as of the March 31, 2022:

Weighted

Weighted

Average

Remaining

Aggregate

Number of

Exercise

Life

Intrinsic

Warrants

Price

In Years

Value

Outstanding, March 31, 2022

142,604,000

0.0515

4.39

2,405,050

Options

Stock options for employees, directors or consultants that vest immediately, are valued at the date of award, which does not precede the approval date, and compensation cost is recognized in the period the options are vested. Stock options generally become exercisable on the date of grant and expire based on the terms of each grant.

The estimated fair value of options for common stock granted is determined using the Black-Scholes option pricing model. The expected dividend yield is based on the average annual dividend yield as of the grant date. Expected volatility is based on the historical volatility of our stock. The risk-free interest rate is based on the U.S. Treasury Constant Maturity rates as of the grant date. The expected life of the option is based on historical exercise behavior and expected future experience.

On June 8, 2020, the Board of Directors consented to a share exchange agreement with holders of 21,500,000 options awarded on August 7, 2019. The agreement allows for holders to exchange their options for rule 144 common stock at an exchange rate of 0.6 shares per 1 option. The modification of these options did not result in any additional compensation because there was no change in the fair value. During the three months ended March 31, 2022, 1,500,000 options were exchanged for 900,000 shares that were issued under the executed exchange agreement.

On March 23, 2022 the Company granted 950,000 options at an average grant date fair value of $0.055 determined using the Black-Scholes option pricing model. The options were granted to an employee and independent contractor for the Company.

The following table summarizes the Company’s option activity during the three-month period ended March 31, 2022:

Weighted

Weighted

Average

Remaining

Aggregate

Number of

Exercise

Life

Intrinsic

Options

Price

In Years

Value

Outstanding, December 31, 2021

53,711,609

0.093

Options granted

950,000

0.055

Exchanged for common stock

(1,500,000

)

0.041

Outstanding, March 31, 2022

53,161,609

0.093

3.98

72,500

Exercisable, March 31, 2022

52,911,609

0.093

3.98

72,500

The following table summarizes the Company’s options as of March 31, 2022:

				Weighted
		*Outstanding*		*Average*		*Exercisable*
*Exercise*		*Number of*		*Remaining Life*		*Number of*
*Price*		*Options*		*In Years*		*Options*

$	0.041		12,500,000		2.35		12,500,000
$	0.055		950,000		5.00		950,000
$	0.065		1,000,000		3.25		750,000
$	0.105		38,500,000		4.50		38,500,000
$	0.240		208,160		4.97		208,160
$	70.260		3,449		0.25		3,449
*Total*			53,161,609		3.98		52,911,609

Litigation, Claims, and Assessments

The Company may be involved in legal proceedings, claims and assessments arising in the ordinary course of business. In the opinion of management, such matters are currently not expected to have a material impact on the Company’s condensed consolidated financial statements. The Company records legal costs associated with loss contingencies as incurred and accrues for all probable and estimable settlements.

Leases

The Company is currently leasing office space in Ann Arbor, Michigan on a month-to-month basis at a rate of $800 per month. On December 14, 2021, the Company entered into an annual lease of a wet laboratory in the same facility as the Company’s office headquarters. The annual rent obligation is $12,600 payable in equal monthly installments. The Company began using the space in March of 2022. Rent expense for the operating leases was $4,707 and $3,780 for the three months ended March 31, 2022 and 2021, respectively.

Supply Agreement

During June 2020, the Company entered into a supply agreement with Evonik Operations GmbH to purchase 500 grams of cyclohexasilane, Si6H12 (CHS) for $185,000. The supply agreement was originally valid until March 31, 2021, however, due to delays resulting from Covid-19 and production delays, both companies agreed to extend the contract duration until all 500 grams of cyclohexasilane is delivered by Evonik. The Company paid Evonik Operations GmbH $92,500 on July 20, 2020, to initiate production of CHS, in accordance with the agreement. Evonik has produced and delivered 150 grams of CHS as of March 31, 2022 and upon remaining product delivery and invoicing, the Company will owe the remaining $92,500.

Significant Accounting Policies (Policies)

3 Months Ended

Mar. 31, 2022

Accounting Policies [Abstract]

Consolidation, Policy [Policy Text Block]

Principles of Consolidation

Use of Estimates, Policy [Policy Text Block]

Use of Estimates

The preparation of condensed consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenues, expenses and the disclosure of contingent assets and liabilities. Actual results could differ from the estimates and assumptions used.

Property, Plant and Equipment, Policy [Policy Text Block]

Property and Equipment

Property and equipment is recorded at cost. Depreciation is recorded over the estimated useful lives using the straight-line method. Maintenance and repairs are expensed as incurred; major improvements and betterments are capitalized.

Goodwill and Intangible Assets, Intangible Assets, Policy [Policy Text Block]

Intangibles

Intangible assets consist of purchased patents and capitalized website costs. Intangible assets are recorded at the fair value as of the date of acquisition, and intangible assets with finite lives are amortized on a straight-line basis over their estimated useful lives.

Goodwill and Intangible Assets, Goodwill, Policy [Policy Text Block]

Goodwill

The Company evaluates the carrying value of goodwill on an annual basis and between annual evaluations if events occur or circumstances change that would more likely than not reduce the fair value of goodwill below its carrying amount. When assessing whether goodwill is impaired, management considers first a qualitative approach to evaluate whether it is more likely than not the fair value of the goodwill is below its carrying amount; if so, management considers a quantitative approach by analyzing changes in performance and market-based metrics as compared to those used at the time of the initial acquisition. For the periods presented, no impairment charges were recognized.

Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]

Impairment of Long-Lived Assets

Long-lived assets, such as property and equipment and intangible assets, are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. If circumstances require a long-lived asset or asset group be tested for possible impairment, the Company first compares undiscounted cash flows expected to be generated by that asset or asset group to its carrying value. If the carrying value of the long-lived asset or asset group is not recoverable on an undiscounted cash flow basis, impairment is recognized to the extent that the carrying value exceeds its fair value. Fair value is determined through various valuation techniques including discounted cash flow models, quoted market values and third-party independent appraisals, as considered necessary.

Fair Value of Financial Instruments, Policy [Policy Text Block]

Fair Value of Financial Instruments

The following methods and assumptions were used to estimate the fair value of each class of financial instrument held by the Company:

Current assets and current liabilities – The carrying value approximates fair value due to the short maturity of these items.

Notes payable – The fair value of the Company’s notes payable has been estimated by the Company based upon the liability’s characteristics, including interest rates, embedded instruments and conversion discounts. The carrying value approximates fair value.

Earnings Per Share, Policy [Policy Text Block]

Basic and Diluted Loss Per Common Share

Basic loss per common share is computed by dividing net loss by the weighted average number of vested common shares outstanding during the period. Diluted loss per share reflects the potential dilution that could occur if securities or other instruments to issue common stock were exercised or converted into common stock. The following securities are excluded from the calculation of weighted average dilutive common shares because their inclusion would have been anti-dilutive:

	March 31,
	2022		2021
Options		53,161,609		18,212,174
Warrants		142,604,000		142,604,000
Series A convertible preferred stock		115,000		115,000
Convertible debt		39,836,388		47,720,365
Total potentially dilutive shares		235,716,997		208,651,539

Research and Development Expense, Policy [Policy Text Block]

Research and Development

Research and development costs are expensed as incurred.

Subsequent Events, Policy [Policy Text Block]

Subsequent Events

The Company evaluates events that have occurred after the balance sheet date but before the condensed consolidated financial statements are issued. Based upon the evaluation, the Company did not identify any recognized or non-recognized subsequent events that would have required adjustment or disclosure in the consolidated financial statements.

Income Tax, Policy [Policy Text Block]

Income Taxes

The Company accounts for income taxes under an asset and liability approach that requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been recognized in the Company’s consolidated financial statements or tax returns. In estimating future tax consequences, the Company generally considers all expected future events other than enactments of changes in tax laws or rates. The effect on deferred tax assets and liabilities of a change in tax rates will be recognized as income or expense in the period that includes the enactment date. A valuation allowance is established when necessary to reduce deferred tax assets to the amount expected to be realized.

The Company’s tax benefits are fully offset by a valuation allowance due to the uncertainty that the deferred tax assets would be realized. Management considers the likelihood of changes by taxing authorities in its filed income tax returns and recognizes a liability for or discloses potential changes that management believes are more likely than not to occur upon examination by tax authorities. Management has not identified any uncertain tax positions in filed income tax returns that require recognition or disclosure in the accompanying consolidated financial statements.

New Accounting Pronouncements, Policy [Policy Text Block]

Recent Accounting Pronouncements

The following is a summary of recent accounting pronouncement recently adopted by the Company:

In May 2021, the FASB issued ASU 2021-04, Issuer’s Accounting for Certain Modifications or Exchanges of Freestanding Equity-Classified Written Call Options which clarifies the accounting for a modification or an exchange of a freestanding equity-classified written call option that remains equity classified after a modification or exchange and the related EPS effects of such transaction if recognized as an adjustment to equity. The Company adopted ASU 2021-04 on January 1, 2022. The Company will consider this guidance for modifications or exchanges of freestanding equity-classified written call options.

Note 2 - Summary of Significant Accounting Policies (Tables)

3 Months Ended

Mar. 31, 2022

Notes Tables

Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]

	March 31,
	2022		2021
Options		53,161,609		18,212,174
Warrants		142,604,000		142,604,000
Series A convertible preferred stock		115,000		115,000
Convertible debt		39,836,388		47,720,365
Total potentially dilutive shares		235,716,997		208,651,539

Note 3 - Intangibles (Tables)

3 Months Ended

Mar. 31, 2022

Notes Tables

Schedule of Finite-Lived Intangible Assets [Table Text Block]

	March 31,			December 31,
Patents	*2022*			*2021*
Gross Carrying Amount	$	1,400,000		$	1,400,000
Accumulated Amortization		(441,260	)		(421,203	)
	$	958,740		$	978,797

Note 4 - Notes Payable (Tables)

3 Months Ended

Mar. 31, 2022

Notes Tables

Schedule of Long-Term Debt Instruments [Table Text Block]

	March 31,			December 31,
Long term debt:	2022			2021
10% Promissory note due January 2024	$	1,310,617		$	1,310,617
Less:
Warrants issued		(82,672	)		(93,929	)
Debt issue costs		(25,694	)		(29,171	)
Total long term debt	$	1,202,251		$	1,187,518

- Definition

Tabular disclosure of long-debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the entity, if longer.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.22)
-URI https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 3
-Subparagraph (SX 210.12-04(a))
-URI https://asc.fasb.org/extlink&oid=120395691&loc=d3e24072-122690

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 835
-SubTopic 30
-Section 45
-Paragraph 1A
-URI https://asc.fasb.org/extlink&oid=124435984&loc=d3e28541-108399

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 6
-URI https://asc.fasb.org/extlink&oid=126973232&loc=d3e21506-112644

Reference 5: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 20
-Section 55
-Paragraph 69B
-URI https://asc.fasb.org/extlink&oid=123466577&loc=SL123495735-112612

Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 835
-SubTopic 30
-Section 45
-Paragraph 2
-URI https://asc.fasb.org/extlink&oid=124435984&loc=d3e28551-108399

Reference 7: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 20
-Section 55
-Paragraph 69E
-URI https://asc.fasb.org/extlink&oid=123466577&loc=SL123495743-112612

Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 7
-URI https://asc.fasb.org/extlink&oid=126973232&loc=d3e21521-112644

Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 8
-URI https://asc.fasb.org/extlink&oid=126973232&loc=d3e21538-112644

Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 470
-Section 50
-Paragraph 3
-URI https://asc.fasb.org/extlink&oid=123599511&loc=d3e64711-112823

Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 835
-SubTopic 30
-Section 55
-Paragraph 8
-URI https://asc.fasb.org/extlink&oid=114775985&loc=d3e28878-108400

Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 3
-URI https://asc.fasb.org/extlink&oid=126973232&loc=d3e21475-112644

+ Details

Note 5 - Commitments and Contingencies (Tables)

3 Months Ended

Mar. 31, 2022

Notes Tables

Warrant Activity [Table Text Block]

Weighted

Weighted

Average

Remaining

Aggregate

Number of

Exercise

Life

Intrinsic

Warrants

Price

In Years

Value

Outstanding, March 31, 2022

142,604,000

0.0515

4.39

2,405,050

Disclosure of Share-Based Compensation Arrangements by Share-Based Payment Award [Table Text Block]

Weighted

Weighted

Average

Remaining

Aggregate

Number of

Exercise

Life

Intrinsic

Options

Price

In Years

Value

Outstanding, December 31, 2021

53,711,609

0.093

Options granted

950,000

0.055

Exchanged for common stock

(1,500,000

)

0.041

Outstanding, March 31, 2022

53,161,609

0.093

3.98

72,500

Exercisable, March 31, 2022

52,911,609

0.093

3.98

72,500

Share-Based Payment Arrangement, Option, Exercise Price Range [Table Text Block]

				Weighted
		*Outstanding*		*Average*		*Exercisable*
*Exercise*		*Number of*		*Remaining Life*		*Number of*
*Price*		*Options*		*In Years*		*Options*

$	0.041		12,500,000		2.35		12,500,000
$	0.055		950,000		5.00		950,000
$	0.065		1,000,000		3.25		750,000
$	0.105		38,500,000		4.50		38,500,000
$	0.240		208,160		4.97		208,160
$	70.260		3,449		0.25		3,449
*Total*			53,161,609		3.98		52,911,609

Note 2 - Summary of Significant Accounting Policies (Details Textual) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Goodwill, Impairment Loss	$ 0	$ 0

Note 2 - Business and Summary of Significant Accounting Policies - Antidilutive Securities Excluded From Computation of Earnings Per Share (Details) - shares	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
potentially dilutive shares (in shares)	235,716,997	208,651,539
Options [Member]
potentially dilutive shares (in shares)	53,161,609	18,212,174
Warrant [Member]
potentially dilutive shares (in shares)	142,604,000	142,604,000
Series A Convertible Preferred Stock [Member]
potentially dilutive shares (in shares)	115,000	115,000
Convertible Debt Securities [Member]
potentially dilutive shares (in shares)	39,836,388	47,720,365

Note 3 - Intangibles (Details Textual) - USD ($)	Mar. 31, 2022	Dec. 31, 2021
Finite-Lived Intangible Assets, Net, Ending Balance	$ 968,947	$ 989,604
Patents [Member]
Finite-Lived Intangible Asset, Expected Amortization, Year One	80,000
Finite-Lived Intangible Asset, Expected Amortization, Year Two	80,000
Finite-Lived Intangible Asset, Expected Amortization, Year Three	80,000
Finite-Lived Intangible Asset, Expected Amortization, Year Four	80,000
Finite-Lived Intangible Asset, Expected Amortization, Year Five	80,000
Finite-Lived Intangible Asset, Expected Amortization, after Year Five	80,000
Finite-Lived Intangible Assets, Net, Ending Balance	958,740	978,797
Finite-Lived Intangible Assets, Accumulated Amortization	441,260	421,203
Computer Software, Intangible Asset [Member]
Finite-Lived Intangible Asset, Expected Amortization, Year One	2,400
Finite-Lived Intangible Asset, Expected Amortization, Year Two	2,400
Finite-Lived Intangible Asset, Expected Amortization, Year Three	2,400
Finite-Lived Intangible Asset, Expected Amortization, Year Four	2,400
Finite-Lived Intangible Asset, Expected Amortization, Year Five	2,400
Finite-Lived Intangible Assets, Net, Ending Balance		12,007
Finite-Lived Intangible Assets, Accumulated Amortization	$ 1,800	$ 1,200

Note 3 - Intangibles - Schedule of Patents (Details) - USD ($)	Mar. 31, 2022	Dec. 31, 2021
Finite-Lived Intangible Assets, Net, Ending Balance	$ 968,947	$ 989,604
Patents [Member]
Gross Carrying Amount	1,400,000	1,400,000
Accumulated Amortization	(441,260)	(421,203)
Finite-Lived Intangible Assets, Net, Ending Balance	$ 958,740	$ 978,797

Note 4 - Notes Payable (Details Textual) - USD ($)		3 Months Ended		12 Months Ended
Note 4 - Notes Payable (Details Textual) - USD ($)	Oct. 04, 2019	Mar. 31, 2022	Mar. 31, 2021	Dec. 31, 2021
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)		$ 0.0515
Warrant Issued in Connection With Credit Agreement [Member]
Debt Conversion, Converted Instrument, Warrants or Options Issued (in shares)		0
Warrant Issued in Connection With Credit Agreement [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)	3,000,000
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)	$ 0.052
Amortization Expense Associated With Warrants		$ 11,257	$ 11,088
Credit Agreement And Note [Member]
Debt Instrument, Interest Rate, Stated Percentage	10.00%	10.00%		10.00%
Debt Agreement, Maximum Borrowing Capacity	$ 2,500,000
Debt Instrument, Number of Tranches	16
Proceeds from Notes Payable, Total				$ 2,170,000
Debt Instrument, Notes Payable, Portion Not Advanced		$ 330,000
Debt Instrument, Period of Monthly Advance Interest Payments (Month)	12 months
Debt Instrument, Convertible, Threshold Percentage of Stock Price Trigger	70.00%
Debt Instrument, Convertible, Threshold Trading Days	15
Debt Instrument, Convertible, Conversion Price (in dollars per share)	$ 0.0329
Line of Credit Facility, Commitment Fee Percentage	3.00%
Amortization Associated With Commitment Fee		$ 3,476	3,656
Credit Agreement And Note [Member] \| Minimum [Member]
Debt Instrument, Amount Funded in Each Monthly Tranche	$ 125,000
Credit Agreement And Note [Member] \| Maximum [Member]
Debt Instrument, Amount Funded in Each Monthly Tranche	$ 175,000
Warrant Issued in Connection With Credit Agreement [Member]
Allocated Cost of Warrants			$ 62,784

Note 4 - Debt - Schedule of Debt (Details) - USD ($)	Mar. 31, 2022	Dec. 31, 2021
Total long term debt	$ 1,202,251	$ 1,187,518
Credit Agreement And Note [Member]
10% Promissory note due January 2024	1,310,617	1,310,617
Warrants issued	(82,672)	(93,929)
Debt issue costs	$ (25,694)	$ (29,171)

Note 4 - Debt - Schedule of Debt (Details) (Parentheticals)	Mar. 31, 2022	Dec. 31, 2021	Oct. 04, 2019
Credit Agreement And Note [Member]
Interest rate	10.00%	10.00%	10.00%

Note 5 - Commitments and Contingencies (Details Textual)						3 Months Ended		30 Months Ended
	Mar. 23, 2022 $ / shares shares	Mar. 02, 2021 USD ($) $ / shares shares	Jul. 20, 2020 USD ($)	Jun. 08, 2020 shares	Oct. 04, 2019 $ / shares shares	Mar. 31, 2022 USD ($) $ / shares shares	Mar. 31, 2021 USD ($)	Mar. 31, 2022 USD ($) $ / shares shares	Dec. 14, 2021 USD ($)	Sep. 30, 2020 USD ($)
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) \| $ / shares						$ 0.0515		$ 0.0515
Share Exchange Agreement, Number of Options Authorized (in shares)				21,500,000
Share Exchange Agreement, Exchange Ratio				0.6
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exchanged (in shares)						1,500,000
Stock Issued During Period, Shares, Stock Options Exchanged for Common Shares (in shares)						900,000
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross (in shares)	950,000					950,000
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value (in dollars per share) \| $ / shares	$ 0.055
Operating Lease, Expense \| $						$ 4,707	$ 3,780
Evonik Operations GmbH [Member]
Purchase Obligation, Total \| $						92,500		$ 92,500		$ 185,000
Payments for Research and Development, Supply Agreement \| $			$ 92,500
Ann Arbor, Michigan [Member]
Operating Lease, Payments \| $						$ 800
Ann Arbor, Michigan [Member] \| Building, Wet laboratory [Member]
Lessee, Operating Lease, Liability, to be Paid, Total \| $									$ 12,600
Private Placement [Member]
Stock Issued During Period, Shares, New Issues (in shares)		23,500,000
Proceeds from Issuance or Sale of Equity, Total \| $		$ 6,000,000
Warrant Issued in Connection With Credit Agreement [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)					3,000,000
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) \| $ / shares					$ 0.052
Class of Warrant or Right, Number of Warrants Issued Per Dollar in the Event of Funding Deviation (in shares)					1.2
Class of Warrant or Right, Issued During Period (in shares)								2,604,000
Warrant Issued in Connection With Credit Agreement [Member] \| Minimum [Member]
Class of Warrant or Right, Issued Monthly (in shares)					150,000
Warrant Issued in Connection With Credit Agreement [Member] \| Maximum [Member]
Class of Warrant or Right, Issued Monthly (in shares)					210,000
Pre-funded Warrant [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)		51,500,000
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) \| $ / shares		$ 0.0001
Class of Warrant or Right, Purchase Price of Warrants or Rights (in dollars per share) \| $ / shares		$ 0.08
Warrants [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)		82,500,000
Class of Warrant or Right, Purchase Price of Warrants or Rights (in dollars per share) \| $ / shares		$ 0.0799
Placement Agent Warrants [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)		6,000,000
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) \| $ / shares		$ 0.10
Warrants Ownership Percentage, Maximum Limit		8.00%

Note 5 - Commitments and Contingencies - Warrants (Details)	3 Months Ended
	Mar. 31, 2022 USD ($) $ / shares shares
Outstanding, number of warrants (in shares) \| shares	142,604,000
Outstanding, weighted-average exercise price (in dollars per share) \| $ / shares	$ 0.0515
Outstanding, weighted-average remaining life (Year)	4 years 4 months 20 days
Outstanding, aggregate intrinsic value \| $	$ 2,405,050

Note 5 - Commitments and Contingencies - Option Activity (Details) - USD ($)		3 Months Ended
	Mar. 23, 2022	Mar. 31, 2022
Options granted (in shares)	950,000	950,000
Granted, Weighted Average Exercise Price (in dollars per share)		$ 0.055
Exchanged for common stock (in shares)		(1,500,000)
Share-Based Payment Arrangement, Option [Member]
Outstanding (in shares)		53,711,609
Outstanding, Weighted Average Exercise Price (in dollars per share)		$ 0.093
Exchanged for common stock (in shares)		(1,500,000)
Exchanged for common stock, Weighted Average Exercise Price (in dollars per share)		$ 0.041
Outstanding (in shares)		53,161,609
Outstanding, Weighted Average Exercise Price (in dollars per share)		$ 0.093
Outstanding, Weighted Average Remaining Life in Years (Year)		3 years 11 months 23 days
Outstanding, Aggregate intrinsic value		$ 72,500
Exercisable (in shares)		52,911,609
Exercisable, Weighted Average Exercise Price (in dollars per share)		$ 0.093
Exercisable, Weighted Average Remaining Life (Year)		3 years 11 months 23 days
Exercisable, Aggregate intrinsic value		$ 72,500

Note 5 - Commitments and Contingencies - Shares Authorized Under Stock Option Plans (Details)	3 Months Ended
	Mar. 31, 2022 $ / shares shares
Option Outstanding, Number Of Options (in shares)	53,161,609
Option Exercisable, Weighted Average Remaining Life In Years (Year)	3 years 11 months 23 days
Option Exercisable, Number Of Options (in shares)	52,911,609
Exercise Price Range One [Member]
Option Outstanding, Exercise Price (in dollars per share) \| $ / shares	$ 0.041
Option Outstanding, Number Of Options (in shares)	12,500,000
Option Exercisable, Weighted Average Remaining Life In Years (Year)	2 years 4 months 6 days
Option Exercisable, Number Of Options (in shares)	12,500,000
Exercise Price Range Two [Member]
Option Outstanding, Exercise Price (in dollars per share) \| $ / shares	$ 0.055
Option Outstanding, Number Of Options (in shares)	950,000
Option Exercisable, Weighted Average Remaining Life In Years (Year)	5 years
Option Exercisable, Number Of Options (in shares)	950,000
Exercise Price Range Three [Member]
Option Outstanding, Exercise Price (in dollars per share) \| $ / shares	$ 0.065
Option Outstanding, Number Of Options (in shares)	1,000,000
Option Exercisable, Weighted Average Remaining Life In Years (Year)	3 years 3 months
Option Exercisable, Number Of Options (in shares)	750,000
Exercise Price Range Four [Member]
Option Outstanding, Exercise Price (in dollars per share) \| $ / shares	$ 0.105
Option Outstanding, Number Of Options (in shares)	38,500,000
Option Exercisable, Weighted Average Remaining Life In Years (Year)	4 years 6 months
Option Exercisable, Number Of Options (in shares)	38,500,000
Exercise Price Range Five [Member]
Option Outstanding, Exercise Price (in dollars per share) \| $ / shares	$ 0.240
Option Outstanding, Number Of Options (in shares)	208,160
Option Exercisable, Weighted Average Remaining Life In Years (Year)	4 years 11 months 19 days
Option Exercisable, Number Of Options (in shares)	208,160
Exercise Price Range Six [Member]
Option Outstanding, Exercise Price (in dollars per share) \| $ / shares	$ 70.260
Option Outstanding, Number Of Options (in shares)	3,449
Option Exercisable, Weighted Average Remaining Life In Years (Year)	3 months
Option Exercisable, Number Of Options (in shares)	3,449